Dr Greg Walker is part of an exciting project on Novel Peptide Vaccines for Broad Application which has been successful in obtaining a grant of $9.7 million, over 5 years, funded by New Zealand's Ministry of Business, Innovation and Employment (MBIE).
The technology can be used to design new treatments for cancer, as well as infectious disease and allergy. The initial focus will centre on cancer immunotherapy.
Along with the Ferrier Research Institute, and the Malaghan Institute of Medical Research, Dr Walker's group will carry out the formulation of vaccines into various dosage forms.
The technology will be commercialised by the newly-formed Wellington-based company Avalia (https://avaliaimmunotherapies.com/)
PhD opportunity
Dr Walker is looking for graduate students to undertake PhD research in the formulation of these new vaccines. If anyone is interested, please contact Greg on greg.walker@otago.ac.nz with a copy a current CV.